PURPOSE: Preliminary reports suggest that leukemic cell expression of CD56, a neural cell
adhesion molecule, is associated with adverse clinical outcome in either acute myeloid …

The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been
associated with short remission duration and extramedullary relapse. We investigated the …

All-trans retinoic acid (ATRA) is an essential component of the treatment of acute
promyelocytic leukemia (APL), but the optimal timing and duration remain to be determined …

All-trans retinoic acid (RA) has proven a major advance in the treatment of acute
promyelocytic leukemia (APL). However, the proper management of patients who present …

PURPOSE: Blast expression of CD56 is frequent in patients with t (8; 21)(q22; q22) acute
myeloid leukemia and is associated with an inferior outcome. The expression of CD56 has …

Expression of CD 56 has recently been introduced as one of the adverse prognostic factors
in acute promyelocytic leukemia (APL). However, the clinical significance of CD 56 antigen …

The vitamin A derivative, all-trans retinoic acid (ATRA), induces differentiation of leukaemic
promyelocytes in patients with acute promyelocytic leukaemia (APL). As a result, the majority …

The incidence of early death in a large population of unselected patients with acute
promyelocytic leukemia (APL) remains unknown because of the paucity of outcome data …

All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia
(APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted …

To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy
with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; …